The global biomarkers market size reached US$ 68.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 139.8 Billion by 2028, exhibiting a growth rate (CAGR) of 11.5% during 2023-2028.
Biomarkers, also known as biological markers, are molecules or genes that are used as indicators of the health or status of an organ, tissue, or cell. In addition to blood and bodily fluids, biomarkers are also found in tissues. In the discovery and development of new drugs, biomarkers are used for risk assessment, molecular diagnostics, disease diagnosis, DNA fingerprinting, and eliminating complexity. As a result, they play a crucial role in improving the drug development process, drug validation and testing, sample preparation and assay development. Biomarkers are often integrated with key imaging technologies that can provide clear images of oncology tumors and other problems while also eliminating the possibility of radiation exposure during CT scans and MRI scans.
Biomarkers Market Trends:
The market is majorly driven by the rising incidences of numerous chronic diseases among the masses, particularly in the geriatric population. In addition to this, the increasing implementation of biomarkers in infectious disease diagnosis is propelling the market. Moreover, continual developments in biomarker-based diagnostics, such as biomarker signatures resulting in faster drug development, non-invasive testing, and early diagnosis, are also creating a positive market outlook. In line with this, the rapid utilization of biomarkers in the development of companion diagnostics to identify drug target molecules is providing an impetus to the market. Also, the escalating demand for personalized medicine, along with a paradigm shift toward biomarker studies from conventional pathophysiology and epidemiology methods, is fueling the market. Furthermore, a considerable rise in the number of contract research organizations facilitating cost-efficient clinical trials are creating a positive market outlook. Some of the other factors contributing to the market include extensive research and development (R&D) activities and the increasing medical expenditure.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global biomarkersmarket report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, type, disease, application and end user.
Breakup by Product:
Breakup by Type:
Breakup by Disease:
Breakup by Application:
Drug Discovery and Development
Breakup by End User:
Pharmaceutical and Biotechnology Companies
Diagnostic and Research Laboratories
Hospitals and Specialty Clinics
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Epigenomics AG, Eurofins Scientific SE, Merck KGaA, Perkinelmer Inc., Qiagen N.V, Quanterix Corporation, SphingoTec GmbH and Thermo Fisher Scientific Inc.
Base Year of the Analysis
Product, Type, Disease, Application, End User, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Agilent Technologies Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Epigenomics AG, Eurofins Scientific SE, Merck KGaA, Perkinelmer Inc., Qiagen N.V, Quanterix Corporation, SphingoTec GmbH and Thermo Fisher Scientific Inc.
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global biomarkers market was valued at US$ 68.2 Billion in 2022.
We expect the global biomarkers market to exhibit a CAGR of 11.5% during 2023-2028.
The rising integration of biomarkers with advanced imaging technologies that can provide clear images of oncology tumors and other problems while eliminating the possibility of radiation exposure during CT scans and MRI scans is primarily driving the global biomarkers market.
The sudden outbreak of the COVID-19 pandemic has led to the growing utilization of biomarkers to discover and develop new drugs for combating the spread of the coronavirus infection.
Based on the product, the global biomarkers market can be segmented into consumables, services, and software. Currently, consumables hold the majority of the total market share.
Based on the type, the global biomarkers market has been divided into efficacy biomarkers, safety biomarkers, and validation biomarkers. Among these, safety biomarkers currently exhibit a clear dominance in the market.
Based on the disease, the global biomarkers market can be categorized into cancer, cardiovascular disorders, neurological disorders, immunological disorders, renal disorders, and others. Currently, cancer accounts for the majority of the global market share.
Based on the application, the global biomarkers market has been segregated into diagnostics, drug discovery and development, personalized medicine, and others, where drug discovery and development currently holds the largest market share.
Based on the end user, the global biomarkers market can be bifurcated into pharmaceutical and biotechnology companies, diagnostic and research laboratories, hospitals and specialty clinics, and others. Currently, diagnostic and research laboratories exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global biomarkers market include Agilent Technologies Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Epigenomics AG, Eurofins Scientific SE, Merck KGaA, Perkinelmer Inc., Qiagen N.V, Quanterix Corporation, SphingoTec GmbH, and Thermo Fisher Scientific Inc.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.